Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cyclacel Pharmaceuti (CYCC)

Cyclacel Pharmaceuti (CYCC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,768
  • Shares Outstanding, K 17,199
  • Annual Sales, $ 150 K
  • Annual Income, $ -7,290 K
  • 60-Month Beta 3.21
  • Price/Sales 71.46
  • Price/Cash Flow N/A
  • Price/Book 0.77
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.59
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/13/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.150 on 07/13/16
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.15
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.18
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.37 +69.22%
on 11/14/19
0.79 -21.14%
on 12/09/19
+0.25 (+64.76%)
since 11/13/19
3-Month
0.32 +95.66%
on 10/22/19
0.79 -21.14%
on 12/09/19
+0.21 (+49.07%)
since 09/13/19
52-Week
0.28 +122.57%
on 08/13/19
1.18 -46.94%
on 03/25/19
-0.19 (-22.89%)
since 12/13/18

Most Recent Stories

More News
Cyclacel's CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, today announced study design...

CYCC : 0.63 (unch)
Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results

- Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent -

CYCC : 0.63 (unch)
Cyclacel Pharmaceuticals to Release Third Quarter 2019 Financial Results

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter...

CYCC : 0.63 (unch)
Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced that data from Cyclacel's...

CYCC : 0.63 (unch)
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that...

CYCC : 0.63 (unch)
Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced treatment of the...

CYCC : 0.63 (unch)
Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that...

CYCC : 0.63 (unch)
Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results

- Conference Call Scheduled August 13, 2019 at 4:30 p.m. ET -

CYCC : 0.63 (unch)
Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second...

CYCC : 0.63 (unch)
Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced treatment of the...

CYCC : 0.63 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade CYCC with:

Business Summary

CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside...

See More

Key Turning Points

2nd Resistance Point 0.72
1st Resistance Point 0.67
Last Price 0.63
1st Support Level 0.58
2nd Support Level 0.54

See More

52-Week High 1.18
Fibonacci 61.8% 0.84
Fibonacci 50% 0.73
Last Price 0.63
Fibonacci 38.2% 0.62
52-Week Low 0.28

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar